VILTADI, MICHELA
 Distribuzione geografica
Continente #
NA - Nord America 1.160
EU - Europa 507
AS - Asia 238
SA - Sud America 2
Totale 1.907
Nazione #
US - Stati Uniti d'America 1.139
DE - Germania 110
SG - Singapore 89
IE - Irlanda 84
CN - Cina 82
SE - Svezia 71
IT - Italia 67
UA - Ucraina 43
RU - Federazione Russa 41
GB - Regno Unito 26
HK - Hong Kong 24
CA - Canada 21
IN - India 14
DK - Danimarca 11
FI - Finlandia 11
BE - Belgio 10
ID - Indonesia 9
VN - Vietnam 9
FR - Francia 8
PL - Polonia 7
NL - Olanda 6
TR - Turchia 6
CZ - Repubblica Ceca 3
KR - Corea 3
BG - Bulgaria 2
AT - Austria 1
BR - Brasile 1
CH - Svizzera 1
CL - Cile 1
EE - Estonia 1
ES - Italia 1
MD - Moldavia 1
MY - Malesia 1
NO - Norvegia 1
RS - Serbia 1
YE - Yemen 1
Totale 1.907
Città #
Ann Arbor 320
Woodbridge 117
Fairfield 91
Wilmington 89
Dublin 81
Singapore 74
Frankfurt am Main 63
Ashburn 55
Houston 54
Chandler 52
Seattle 40
Cambridge 37
Dearborn 37
Jacksonville 33
New York 26
Hong Kong 24
Milan 24
Santa Clara 24
Princeton 18
Shanghai 15
Nanjing 14
Göttingen 12
Altamura 9
Dong Ket 9
Jakarta 9
Brussels 8
Lawrence 8
Ottawa 8
Lodz 7
Munich 7
Lachine 6
Romola 6
Beijing 5
Guangzhou 5
Huizen 5
San Diego 5
Shenyang 5
Bucha 4
Fürstenwalde 4
Helsinki 4
Jiaxing 4
Kilburn 4
Kocaeli 4
Nanchang 4
Norwalk 4
Tianjin 4
Toronto 4
Andover 3
Boardman 3
Brno 3
Hangzhou 3
Hebei 3
St Petersburg 3
Bangalore 2
Daejeon 2
Delhi 2
Edmonton 2
Fremont 2
Gessate 2
Jinan 2
Kiev 2
Mountain View 2
Plovdiv 2
Pune 2
Redmond 2
Rome 2
Schweinfurt 2
Taizhou 2
Washington 2
Zhengzhou 2
Augusta 1
Bajina Basta 1
Baotou 1
Barceloneta 1
Bari 1
Berlin 1
Buffalo 1
Carate Brianza 1
Castelleone 1
Changchun 1
Changsha 1
Chengdu 1
Chieti 1
Chisinau 1
Chiswick 1
Chongqing 1
Dalian 1
Dallas 1
Desio 1
Esslingen am Neckar 1
Falls Church 1
Ferrara 1
Florence 1
Gießen 1
Grafing 1
Hefei 1
Islington 1
Kuala Lumpur 1
Kunming 1
Lappeenranta 1
Totale 1.524
Nome #
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 406
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 245
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 231
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 208
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 189
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 187
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 181
Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib 146
Bosutinib is a Substrate of the ABC Efflux Transporter P-Glycoprotein 121
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 54
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 52
Totale 2.020
Categoria #
all - tutte 6.246
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.246


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020226 0 0 0 0 0 0 58 36 44 49 26 13
2020/2021386 15 21 39 37 36 37 46 42 35 33 14 31
2021/2022147 12 17 25 8 9 14 8 5 8 11 9 21
2022/2023254 25 83 21 20 17 31 6 7 19 17 5 3
2023/2024240 5 5 9 16 34 65 55 7 18 5 0 21
2024/2025194 27 45 39 23 46 14 0 0 0 0 0 0
Totale 2.020